WallStreetZenWallStreetZen

NASDAQ: GALT
Galectin Therapeutics Inc Stock Ownership - Who owns Galectin Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Galectin Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Khurram JamilChief Medical Officer2025-12-174,479$7.04
$31.53kSell
Harold H. ShlevinDirector2025-12-174,706$7.04
$33.12kSell
Harold H. ShlevinDirector2025-12-1719,793$7.04
$139.30kSell
Harold H. ShlevinDirector2025-12-1720,000$1.98
$39.60kBuy
Joel LewisPresident and CEO2025-12-177,829$7.06
$55.24kSell
Joel LewisPresident and CEO2025-12-177,829$2.86
$22.39kBuy
Khurram JamilChief Medical Officer2025-12-178,500$7.04
$59.84kSell
Khurram JamilChief Medical Officer2025-12-178,500$2.50
$21.25kBuy
Khurram JamilChief Medical Officer2025-12-176,463$7.04
$45.50kSell
Khurram JamilChief Medical Officer2025-12-176,463$2.20
$14.22kBuy

1 of 12

GALT insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when GALT insiders and whales buy or sell their stock.

GALT Shareholders

What type of owners hold Galectin Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
10x Fund LP34.54%22,271,880$97.55MInsider
James C. Czirr32.60%21,015,907$92.05MInsider
Rod D. Martin18.70%12,057,197$52.81MInsider
Richard E. Uihlein16.02%10,328,981$45.24MInsider
David Platt13.06%8,418,743$36.87MInsider
Vanguard Group Inc3.49%2,247,967$9.85MInstitution
Osaic Holdings Inc1.90%1,224,724$5.36MInstitution
Joel Lewis1.30%836,592$3.66MInsider
Blackrock Inc1.24%797,669$3.49MInstitution
Geode Capital Management LLC0.98%633,067$2.77MInstitution

1 of 3

GALT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
GALT11.91%88.09%Net SellingNet Selling
PBYI61.30%38.70%Net SellingNet Selling
ZURA49.27%50.73%
ABEO45.73%54.27%Net SellingNet Selling
QSI29.96%47.56%Net SellingNet Selling
View Top Biotech Stocks

Galectin Therapeutics Stock Ownership FAQ

Who owns Galectin Therapeutics?

Galectin Therapeutics (NASDAQ: GALT) is owned by 15.92% institutional shareholders, 117.81% Galectin Therapeutics insiders, and 0.00% retail investors. 10x Fund LP is the largest individual Galectin Therapeutics shareholder, owning 22.27M shares representing 34.54% of the company. 10x Fund LP's Galectin Therapeutics shares are currently valued at $97.55M.

If you're new to stock investing, here's how to buy Galectin Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.